PRINCETON, N.J., March 8 /PRNewswire/ -- Pharmasset is pleased to announce the appointment of Fredric D. Price as a member of the Board of Directors and the Audit Committee. Mr. Price is currently the Chairman of the Board of Directors of Omrix Biopharmaceuticals and Glycadia Pharmaceuticals, and he is a Director of Enobia Pharma. From October 2000 to August 2004, Mr. Price was Chairman and Chief Executive Officer of BioMarin Pharmaceutical Inc., and he was President, Chief Executive Officer and a Director of Applied Microbiology from 1994 to 2000. Mr. Price's prior experience includes being the Chief Financial Officer of Regeneron Pharmaceuticals, Inc., the founder of the strategy consulting firm RxFDP, and a Vice President of Pfizer Pharmaceuticals with both line and staff responsibilities. He is a co-inventor of 12 issued U.S. patents and one U.S. patent application. Mr. Price received a B.A. from Dartmouth College and an M.B.A. from the Wharton School of the University of Pennsylvania.
About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Contact Alan Roemer Vice President, Investor Relations & Corporate Communications alan.roemer@pharmasset.com Office: (609) 613-4125
STATEMENTS IN THIS COMPANY PRESS RELEASE MAY CONSTITUTE FORWARD-LOOKING STATEMENTS AND ARE SUBJECT TO NUMEROUS RISKS AND UNCERTAINTIES, INCLUDING THE FAILURE OF OUR CLINICAL PROGRAMS TO PERFORM AS EXPECTED, THE COMPANY'S ABILITY TO ATTRACT AND RETAIN QUALIFIED PERSONNEL TO CONDUCT THE REQUIRED CLINICAL TRIALS FOR OUR CLINICAL PROGRAMS, THE STATUS OF THE COMPANY'S HCV COLLABORATION WITH ROCHE, THE COMPANY'S FUTURE CAPITAL NEEDS TO FUND THE DEVELOPMENT PROGRAMS, THE COMPANY'S ABILITY TO OBTAIN ADDITIONAL FINANCING, THE COMPANY'S ABILITY TO OBTAIN REQUIRED REGULATORY APPROVALS FOR OUR CLINICAL PROGRAMS, THE DEVELOPMENT OF COMPETITIVE PRODUCTS BY OTHERS, THE EXISTENCE OF THIRD-PARTY PATENT RIGHTS, AND OTHER RISKS INHERENT IN DISCOVERY AND DEVELOPMENT STAGE PROGRAMS AT A BIOTECHNOLOGY COMPANY. THE ACTUAL RESULTS FOR OUR PROGRAMS MAY DIFFER MATERIALLY FROM THOSE ANTICIPATED IN THIS COMPANY PRESS RELEASE. THE COMPANY DISCLAIMS ANY OBLIGATION TO UPDATE THE STATEMENTS CONTAINED IN THIS COMPANY PRESS RELEASE.
Pharmasset, Inc.CONTACT: Alan Roemer, Vice President, Investor Relations & CorporateCommunications of Pharmasset, Inc., +1-609-613-4125,alan.roemer@pharmasset.com
Web site: http://www.pharmasset.com/
